Estandarización de la técnica Real Time PCR para la detección molecular de la mutación V617F en el gen de JAK-2 en neoplasias mieloproliferativas crónicas
C. Pérez N., Liliam León V., Araceli Pinto L., G. Muñoz G., J. Alfaro L., M. Larrondo L
{"title":"Estandarización de la técnica Real Time PCR para la detección molecular de la mutación V617F en el gen de JAK-2 en neoplasias mieloproliferativas crónicas","authors":"C. Pérez N., Liliam León V., Araceli Pinto L., G. Muñoz G., J. Alfaro L., M. Larrondo L","doi":"10.5354/2735-7996.2019.70005","DOIUrl":null,"url":null,"abstract":"V617F mutation in exon 14 of Janus Kinase 2 gene (jak-2) is used as a molecular marker for the diagnosis of Philadelphia negative myeloproliferative neoplasms (Phi-) such as Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Primary Myelofibrosis (MFP). To detect this mutation, we used conventional polymerase chain reaction technique (PCR), a simple and inexpensive technique, however, has some drawbacks that current technology allows to solve. During the last years, more sensitive molecular techniques have been incorporated in clinical practice to support the diagnosis, prognosis and follow-up of hematological patients. For its implementation in the clinical routine should be considered technical and economic aspects, so in this work, we evaluate the Real Time PCR technique as a diagnostic method for the detection of the Jak-2-V617F mutation, using in house primers design. Our result show that the technique implemented has a concordance index of 0.87 with the conventional PCR used in the molecular diagnosis of myeloproliferative neoplasms. In addition, it has the same specificity, greater sensitivity and, shorter execution time in relation to conventional PCR. The implementation of this diagnostic method in our Hospital is technically possible and commercially convenient.","PeriodicalId":287456,"journal":{"name":"Revista Hospital Clínico Universidad de Chile","volume":"6 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2019-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Hospital Clínico Universidad de Chile","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5354/2735-7996.2019.70005","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
V617F mutation in exon 14 of Janus Kinase 2 gene (jak-2) is used as a molecular marker for the diagnosis of Philadelphia negative myeloproliferative neoplasms (Phi-) such as Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Primary Myelofibrosis (MFP). To detect this mutation, we used conventional polymerase chain reaction technique (PCR), a simple and inexpensive technique, however, has some drawbacks that current technology allows to solve. During the last years, more sensitive molecular techniques have been incorporated in clinical practice to support the diagnosis, prognosis and follow-up of hematological patients. For its implementation in the clinical routine should be considered technical and economic aspects, so in this work, we evaluate the Real Time PCR technique as a diagnostic method for the detection of the Jak-2-V617F mutation, using in house primers design. Our result show that the technique implemented has a concordance index of 0.87 with the conventional PCR used in the molecular diagnosis of myeloproliferative neoplasms. In addition, it has the same specificity, greater sensitivity and, shorter execution time in relation to conventional PCR. The implementation of this diagnostic method in our Hospital is technically possible and commercially convenient.
Janus Kinase 2基因(jak-2)外显子14中的V617F突变被用作费城阴性骨髓增殖性肿瘤(Phi-)的诊断分子标记,如真性红细胞增多症(PV)、原发性血小板增多症(ET)和原发性骨髓纤维化(MFP)。为了检测这种突变,我们使用了传统的聚合酶链反应技术(PCR),这是一种简单而廉价的技术,然而,目前的技术可以解决一些缺点。在过去的几年里,更敏感的分子技术已被纳入临床实践,以支持血液病患者的诊断、预后和随访。由于Real Time PCR技术在临床常规应用中需要考虑技术和经济方面的问题,因此在本研究中,我们采用室内引物设计,对Real Time PCR技术作为检测Jak-2-V617F突变的诊断方法进行了评价。结果表明,该技术与常规PCR在骨髓增生性肿瘤分子诊断中的一致性指数为0.87。此外,它具有与传统PCR相同的特异性、更高的灵敏度和更短的执行时间。该诊断方法在我院的实施在技术上是可行的,在商业上是方便的。